Emtricitabine is a cytidine nucleoside analog reverse transcriptase inhibitor (NRTI) that is clinically used to treat HIV infection. This antiviral also displays some efficacy in the treatment of hepatitis B infection. Emtricitabine is typically co-administered with other antiretrovirals; it also inhibits telomerase activity in vitro.
| Cas No. | 143491-57-0 |
|---|---|
| Purity | ≥98% |
| Formula | C8H10FN3O3S |
| Formula Wt. | 247.25 |
| IUPAC Name | 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one |
| Appearance | White to off white powder |
| Store Temp | 4°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | E5178 MSDS PDF |
|---|---|
| Info Sheet | E5178 Info Sheet PDF |
| Brochures | Antivirals Booklet |
Kulkarni R, Hluhanich R, McColl DM, et al. The combined anti-HIV-1 activities of emtricitabine and tenofovir plus the integrase inhibitor elvitegravir or raltegravir show high levels of synergy in vitro. Antimicrob Agents Chemother. 2014 Oct;58(10):6145-50. PMID: 25092710.
Arribas JR, Eron J. Advances in antiretroviral therapy. Curr Opin HIV AIDS. 2013 Jul;8(4):341-9. PMID: 23666392.
Leeansyah E, Cameron PU, Solomon A, et al. Inhibition of telomerase activity by human immunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: a potential factor contributing to HIV-associated accelerated aging. J Infect Dis. 2013 Apr;207(7):1157-65. PMID: 23303810.
